Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2024 | $65.00 | Buy | Goldman |
| 9/17/2024 | $55.00 → $66.00 | Neutral → Outperform | Robert W. Baird |
| 3/20/2024 | Buy | Needham | |
| 2/20/2024 | $60.00 → $70.00 | Neutral → Buy | Mizuho |
| 9/6/2023 | $52.00 | Hold | HSBC Securities |
| 7/19/2023 | $56.00 | Neutral | Robert W. Baird |
| 4/14/2023 | $48.00 | Neutral | Mizuho |
| 12/21/2022 | $62.00 | Equal Weight | Barclays |
8-K - LivaNova PLC (0001639691) (Filer)
IRANNOTICE - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
3 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
3/A - LivaNova PLC (0001639691) (Issuer)
Goldman initiated coverage of LivaNova with a rating of Buy and set a new price target of $65.00
Robert W. Baird upgraded LivaNova from Neutral to Outperform and set a new price target of $66.00 from $55.00 previously
Needham reiterated coverage of LivaNova with a rating of Buy
SC 13G - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 12.3% on a constant-currency basis. Third-quarter U.S. GAAP diluted earnings per share of $0.60 and adjusted diluted earnings per share of $0.90. In October 2024, LivaNova announced the appointment of Susan Podlogar to the Board. Podlogar
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 881946. A replay will be available on
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) Second-quarter revenue of $318.6 million increased 8.4% on a reported basis and 9.6% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 10.8% on a constant-currency basis. Second-quarter U.S. GAAP diluted earnings per share of $0.30 and adjusted diluted earnings per share of $0.93. Franco Poletti named President of Ca
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. "LivaNova's Board of Directors is pleased to welcome Susan Podlogar," said William Kozy, Chair of the Board. "Susan is a visionary leader with three decades of experience in leading business, talent, and cultural transformations at recognized global companies. She possesses a sharp understanding of the ever-changing global business landscape and will be a tremendous asset to the Board." Podlogar's career spans 30 years, holding key g
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci
Long-time Director Andrea Saia to retire from the Board LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the Audit and Compliance Committee. Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December 31, 2023. "The LivaNova Board of Directors is pleased to welcome Chris Barry," said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova. "Chris has spent his career in the medical technology industry, and we look forward to adding his commercial expertise and ability to drive long-term gro
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in November and December: Stifel Healthcare Conference 2024 on Tuesday, November 19 from 11:30 a.m. - 12:00 p.m. Eastern Time, 6th Annual Wolfe Research Healthcare Conference on Wednesday, November 20 from 1:20 - 1:50 p.m. Eastern Time, and Piper Sandler Healthcare Conference on Tuesday, December 3 from 10:00 - 10:25 a.m. Eastern Time. All three fireside chats will stream live with recordings available afterward. To access event
Top-line results compared to baseline at six months: Median apnea-hypopnea index reduction of 66.2% Median oxygen desaturation index reduction of 63.3% LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment arm and the sham arm for the LivaNova aura6000™ System. The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients wi
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 12.3% on a constant-currency basis. Third-quarter U.S. GAAP diluted earnings per share of $0.60 and adjusted diluted earnings per share of $0.90. In October 2024, LivaNova announced the appointment of Susan Podlogar to the Board. Podlogar
Stifel analyst Rick Wise maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $70 to $72.
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $72 price target.